Filing Details
- Accession Number:
- 0001209191-14-067314
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2014-11-07 16:20:00
- Reporting Period:
- 2014-11-05
- Filing Date:
- 2014-11-07
- Accepted Time:
- 2014-11-07 16:20:00
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 875320 | Vertex Pharmaceuticals Inc / Ma | VRTX | Pharmaceutical Preparations (2834) | 043039129 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1557290 | A Stuart Arbuckle | C/O Vertex Pharmaceuticals Incorporated 50 Northern Avenue Boston MA 02210 | Evp\Chief Commercial Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2014-11-05 | 4,250 | $45.11 | 121,514 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2014-11-05 | 2,576 | $112.07 | 118,938 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2014-11-05 | 1,374 | $112.98 | 117,564 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2014-11-05 | 300 | $113.98 | 117,264 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (right to buy) | Disposition | 2014-11-05 | 4,250 | $0.00 | 4,250 | $45.11 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 60,875 | 2023-02-04 | No | 4 | M | Direct |
Reported Non-Derivative Holdings
| Sec. Name | Remaning Holdings | Nature of Ownership | Explanation |
|---|---|---|---|
| Common Stock | 140 | Indirect | 401(k) |
Footnotes
- Transaction made pursuant to Mr. Arbuckle's company approved trading plan under Rule 10b5-1.
- Mr. Arbuckle undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
- Open market sales reported on this line occurred at a weighted average price of $112.07 (range $111.54 to $112.53).
- Open market sales reported on this line occurred at a weighted average price of $112.98 (range $112.60 to $113.46).
- Open market sales reported on this line occurred at a weighted average price of $113.98 (range $113.67 to $114.29).
- The option vests in 16 quarterly installments from 02/05/2013.
Billionaire Hedge Funds
